Use of an immobilised human serum albumin HPLC column as a probe of drug-protein interactions: the reversible binding of valproate.
The reversible binding of valproate to human serum albumin determines a decrease of the binding of ligands that selectively bind to site I, site II, and bilirubin binding site. The binding inhibition was followed by displacement chromatography methodology using increasing concentrations of the competitor, i.e. valproate, in the mobile phase. Significant binding inhibition was observed for drugs binding at site I and site II. The greater displacement was observed for the more retained enantiomer of benzodiazepines and profens. A reduction of the affinity was observed also in the case of phenol red, this compound being selected as representative of bilirubin binding site. Difference circular dichroism spectroscopy was also used to characterise the binding of valproate to human serum albumin. This antiepilectic drug was proved to affect the binding at site I, II, and bilirubin binding site. The data have physiological relevance because significant inhibition of the binding resulted at clinic concentrations of valproate.
Bertucci
C
C
Dipartimento di Scienze Farmaceutiche, Università di Bologna, Italy. bertucci@alma.unibo.it
Andrisano
V
V
Gotti
R
R
Cavrini
V
V
D002942:Circular Dichroism; D006801:Humans; D015335:Molecular Probes; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*; D014635:Valproic Acid / Q000378:metabolism*
D015335:Molecular Probes; D012709:Serum Albumin; D014635:Valproic Acid